SOPHiA GENETICS (NASDAQ:SOPH) and DarioHealth (NASDAQ:DRIO) Head to Head Review

DarioHealth (NASDAQ:DRIO) and SOPHiA GENETICS (NASDAQ:SOPH) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

Risk & Volatility

DarioHealth has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500. Comparatively, SOPHiA GENETICS has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500.

Institutional & Insider Ownership

33.4% of DarioHealth shares are owned by institutional investors. Comparatively, 31.6% of SOPHiA GENETICS shares are owned by institutional investors. 3.5% of DarioHealth shares are owned by insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares DarioHealth and SOPHiA GENETICS’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
DarioHealth	-169.87%	-54.81%	-33.36%
SOPHiA GENETICS	-93.86%	-132.47%	-45.97%

Earnings & Valuation

This table compares DarioHealth and SOPHiA GENETICS”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DarioHealth	$22.36 million	3.17	-$41.71 million	($6.13)	-1.18
SOPHiA GENETICS	$77.27 million	8.78	-$79.00 million	($1.15)	-7.03

DarioHealth has higher earnings, but lower revenue than SOPHiA GENETICS. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than DarioHealth, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for DarioHealth and SOPHiA GENETICS, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DarioHealth	1	1	2	0	2.25
SOPHiA GENETICS	1	1	3	0	2.40

DarioHealth presently has a consensus target price of $10.00, indicating a potential upside of 38.12%. SOPHiA GENETICS has a consensus target price of $10.00, indicating a potential upside of 23.61%. Given DarioHealth’s higher possible upside, equities research analysts plainly believe DarioHealth is more favorable than SOPHiA GENETICS.

About DarioHealth

DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.